Key Leaders - Monkeypox Treatment Industry

The demand for novel medications and vaccinations to treat monkeypox sickness is anticipated to increase as the disease's prevalence rises. Over the projected period, this is also anticipated to fuel the expansion of the global market for monkeypox treatments.For instance, according to information from the Centers for Disease Control and Prevention, there are estimated to be 31,800 confirmed cases of monkeypox worldwide through August 9, 2022, of which 31,425 are in nations that have never previously reported monkeypox. However there are 375 in nations where monkeypox has previously been documented. The Centers for Disease Control and Prevention report that the United States' vaccine supply is not keeping up with demand.

Global Monkeypox Treatment Market is estimated to be valued at US$ 70.4 Million in 2022 and expected to reach US$ 258.6 million by 2030, witnessing a CAGR of 17.7 % over the forecast period (2022-2030).

Prominent Players in the Monkeypox Treatment Industry:

SIGA Technologies, Inc.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. The company was incorporated in 1995 and is headquartered in New York, New York. In July, 2022 SIGA Technologies, Inc.  A commercial-stage pharmaceutical company focused on the health security market, today announced a collaboration with KaliVir Immunotherapeutics to make TPOXX® (tecovirimat) available for use with KaliVir’s proprietary oncolytic vaccinia immunotherapy platform.

Chimerix, Inc.

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark. In February, 2023 Bavarian Nordic A/S announced today that it has entered into an agreement with Emergent BioSolutions Inc. (“Emergent”) to acquire two marketed travel vaccines, Vivotif® for the prevention of typhoid fever and Vaxchora® against cholera.

Sanofi S.A.

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. Sanofi was founded in 1973 and is headquartered in Paris, France.

Emcure Pharma

Emcure Pharmaceuticals Private Limited incorporated in 1981. It has headquarters situated in Pune, India.

*Definition-

Monkeypox was first identified in colonies of monkeys held for study in 1958 after two outbreaks of a condition resembling the pox. This uncommon viral illness is brought on by the monkeypox virus. Zoonotic diseases, such as monkeypox, are spread from animals to people.